Journal of Psychopharmacology最新文献_第5页

Safety, tolerability and pharmacokinetics of the phosphodiesterase 2 inhibitor BI 474121: An overview of phase I randomized trials in healthy volunteers 磷酸二酯酶 2 抑制剂 BI 474121 的安全性、耐受性和药代动力学：健康志愿者 I 期随机试验综述

IF 4.1 3区医学

Journal of Psychopharmacology Pub Date : 2024-09-12 DOI: 10.1177/02698811241273814

Jennifer Schaible, Andreas Scholz, Rainer-Georg Goeldner, Norio Yamamura

{"title":"Safety, tolerability and pharmacokinetics of the phosphodiesterase 2 inhibitor BI 474121: An overview of phase I randomized trials in healthy volunteers","authors":"Jennifer Schaible, Andreas Scholz, Rainer-Georg Goeldner, Norio Yamamura","doi":"10.1177/02698811241273814","DOIUrl":"https://doi.org/10.1177/02698811241273814","url":null,"abstract":"Background:Cognitive impairment associated with schizophrenia predicts poor functional outcomes, but currently no efficacious pharmacotherapies are available.Aims:Four phase I trials examined the safety, tolerability and pharmacokinetics of the phosphodiesterase 2 inhibitor BI 474121, along with potential drug–drug interactions.Methods:Trial 1 evaluated single rising doses (SRDs) of BI 474121 versus placebo in healthy males. The influence of drug formulation and food on drug bioavailability was also examined. Trial 2 evaluated SRD of BI 474121 versus placebo in healthy Japanese males. Trial 3 evaluated multiple rising doses of BI 474121 in healthy young (with/without midazolam) and elderly (without midazolam) participants versus placebo. Trial 4 investigated interactions between itraconazole and single-dose BI 474121 in healthy males.Results/Outcomes:No deaths, serious adverse events (AEs), severe AEs or protocol-specified AEs of special interest were observed. BI 474121 absorbed rapidly during fasting, achieved maximum concentration of analyte in plasma and dose proportionality via tablet formulation, and decreased in a multiphasic manner. BI 474121 steady state occurred within 11 days of multiple oral administration. Multiple doses increased BI 474121 plasma concentrations, but did not alter the time course of plasma concentrations. Urinary excretion of unchanged BI 474121 was negligible. No clinically relevant inhibition or induction of CYP3A4 by BI 474121 was observed. Itraconazole co-administration produced higher exposures of BI 474121 versus BI 474121 alone.Conclusions/Interpretation:BI 474121 demonstrated favourable safety and pharmacokinetic profiles in healthy Caucasian and Japanese individuals, supporting further clinical development.","PeriodicalId":16892,"journal":{"name":"Journal of Psychopharmacology","volume":"46 1","pages":"2698811241273814"},"PeriodicalIF":4.1,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142223995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Response to Letter to the Editor Navigating the challenge of patient selection and scales to measure outcomes in ketamine trials for treatment-resistant depression. 回应致编辑的信在氯胺酮治疗难治性抑郁症的试验中，如何选择患者和测量结果的量表是一项挑战。

IF 4.5 3区医学

Journal of Psychopharmacology Pub Date : 2024-09-12 DOI: 10.1177/02698811241276505

Paul Glue, Neil McNaughton

引用次数: 0

Antipsychotic medication in people with intellectual disability and schizophrenia: A 25-year updated systematic review and cross-sectional study. 智障和精神分裂症患者的抗精神病药物治疗：一项历时 25 年的最新系统回顾和横断面研究。

IF 4.1 3区医学

Journal of Psychopharmacology Pub Date : 2024-09-12 DOI: 10.1177/02698811241276787

Elsa Courtial,Arnaud Pouchon,Mircea Polosan,Clément Dondé

{"title":"Antipsychotic medication in people with intellectual disability and schizophrenia: A 25-year updated systematic review and cross-sectional study.","authors":"Elsa Courtial,Arnaud Pouchon,Mircea Polosan,Clément Dondé","doi":"10.1177/02698811241276787","DOIUrl":"https://doi.org/10.1177/02698811241276787","url":null,"abstract":"OBJECTIVESTo determine the efficacy and safety of antipsychotic medication for treating individuals with a dual diagnosis of intellectual disability (ID) and schizophrenia.METHODSWe systematically reviewed the literature to explore the risks and benefits of antipsychotics for schizophrenia in ID. In addition, a cross-sectional retrospective study on the tolerance profiles of a representative ID and schizophrenia cohort was conducted.RESULTSFrom the systematic search, we retained 18 articles detailing information on 24 cases. In almost all cases, the antipsychotic improved psychotic symptoms (e.g., hallucinations, delusions, disorganization). Negative manifestations were also improved (blunted affects, amotivation, poor rapport), as were challenging behaviors in a few cases. The most commonly reported side effects were neurological (extra-pyramidal, movement disorder, epilepsy) and metabolic manifestations. In the retrospective cross-sectional study, we reported data on 112 participants with comorbid ID and schizophrenia. In all, 103 participants were antipsychotic-treated, of which 39% were on antipsychotic monotherapy. Of these, 35% were in the obesity range, 25% in the hyperglycemic range, and 25% in the dyslipidemia range. The body mass index did not differ between the groups.CONCLUSIONSThis study provides an initial evidence base underpinning the efficacy of antipsychotic drugs on schizophrenia in the ID population. Nevertheless, there may be an increased risk of metabolic side effects, hence, close monitoring of blood glucose, lipids, and weight should be implemented when prescribing antipsychotics to this population.","PeriodicalId":16892,"journal":{"name":"Journal of Psychopharmacology","volume":"143 1","pages":"2698811241276787"},"PeriodicalIF":4.1,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142184613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Navigating the challenge of patient selection and scales to measure outcomes in ketamine trials for treatment-resistant depression 在氯胺酮治疗难治性抑郁症试验中，如何应对患者选择和量表测量结果的挑战

IF 4.1 3区医学

Journal of Psychopharmacology Pub Date : 2024-09-12 DOI: 10.1177/02698811241276505

Sarah Pereira Gomes, Sofia Rodrigues Lima, Fabio Gomes de Matos Souza, Luísa Weber Bisol

引用次数: 0

Blackcurrant (Ribes nigrum L.) improves cholinergic signaling and protects against chronic Scopolamine-induced memory impairment in mice. 黑加仑（Ribes nigrum L.）可改善胆碱能信号传导，防止小鼠因慢性东莨菪碱引起的记忆损伤。

IF 4.1 3区医学

Journal of Psychopharmacology Pub Date : 2024-09-12 DOI: 10.1177/02698811241273776

Pauline da Costa,Maria Rosa C Schetinger,Jucimara Baldissarelli,Naiara Stefanello,Thauan F Lopes,Karine P Reichert,Charles E Assmann,Nathieli B Bottari,Vanessa V Miron,Fermina Francesca A Vargas,Jessié M Gutierres,Ivana Beatrice M da Cruz,Vera Maria Morsch

{"title":"Blackcurrant (Ribes nigrum L.) improves cholinergic signaling and protects against chronic Scopolamine-induced memory impairment in mice.","authors":"Pauline da Costa,Maria Rosa C Schetinger,Jucimara Baldissarelli,Naiara Stefanello,Thauan F Lopes,Karine P Reichert,Charles E Assmann,Nathieli B Bottari,Vanessa V Miron,Fermina Francesca A Vargas,Jessié M Gutierres,Ivana Beatrice M da Cruz,Vera Maria Morsch","doi":"10.1177/02698811241273776","DOIUrl":"https://doi.org/10.1177/02698811241273776","url":null,"abstract":"BACKGROUNDBlackcurrant (Ribes nigrum L.) is a berry rich in anthocyanins, bioactive compounds known for their antioxidant and neuroprotective properties that benefit human health.AIMSThis study aimed to investigate the effects of blackcurrant and its association with Donepezil on memory impairment, cholinergic neurotransmission, and antioxidant systems in a mouse model of amnesia induced by chronic administration of Scopolamine.METHODSAdult male Swiss mice were given saline, blackcurrant (50 mg/kg, orally), and/or Donepezil (5 mg/kg, orally) and/or Scopolamine (1 mg/kg, intraperitoneally).RESULTSBehavioral tests revealed that blackcurrant and/or Donepezil prevented the learning and memory deficits induced by Scopolamine. In the cerebral cortex and hippocampus, blackcurrant and/or Donepezil treatments prevented the increase in acetylcholinesterase and butyrylcholinesterase activities induced by Scopolamine. Scopolamine also disrupted the glutathione redox system and increased levels of reactive species; nevertheless, blackcurrant and/or Donepezil treatments were able to prevent oxidative stress. Furthermore, these treatments prevented the increase in gene expression and protein density of acetylcholinesterase and the decrease in gene expression of the choline acetyltransferase enzyme induced by Scopolamine.CONCLUSIONSFindings suggest that blackcurrant and Donepezil, either alone or in combination, have anti-amnesic effects by modulating cholinergic system enzymes and improving the redox profile. Therefore, blackcurrant could be used as a natural supplement for the prevention and treatment of memory impairment in neurodegenerative diseases.","PeriodicalId":16892,"journal":{"name":"Journal of Psychopharmacology","volume":"53 1","pages":"2698811241273776"},"PeriodicalIF":4.1,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142184623","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Long-read sequencing of CYP2D6 may improve psychotropic prescribing and treatment outcomes: A systematic review and meta-analysis. CYP2D6长读测序可改善精神药物处方和治疗效果：系统综述和荟萃分析。

IF 4.1 3区医学

Journal of Psychopharmacology Pub Date : 2024-09-11 DOI: 10.1177/02698811241268899

Dean Kaptsis,Martin Lewis,Michael Sorich,Malcolm Battersby

{"title":"Long-read sequencing of CYP2D6 may improve psychotropic prescribing and treatment outcomes: A systematic review and meta-analysis.","authors":"Dean Kaptsis,Martin Lewis,Michael Sorich,Malcolm Battersby","doi":"10.1177/02698811241268899","DOIUrl":"https://doi.org/10.1177/02698811241268899","url":null,"abstract":"BACKGROUNDThe enzyme expression (i.e. phenotype) of the Cytochrome P450 2D6 (CYP2D6) gene is highly relevant to the metabolism of psychotropic medications, and therefore to precision medicine (i.e. personalised prescribing).AIMSThis review aims to assess the improvement in CYP2D6 phenotyping sensitivity (IPS) and accuracy (IPA) offered by long-read sequencing (LRS), a new genetic testing technology.METHODSHuman DNA samples that underwent LRS genotyping of CYP2D6 in published, peer-reviewed clinical research were eligible for inclusion. A systematic literature search was conducted until 30 September 2023. CYP2D6 genotypes were translated into phenotypes using the international consensus method. IPS was the percentage of non-normal LRS CYP2D6 phenotypes undetectable with FDA-approved testing (AmpliChip). IPA was the percentage of LRS CYP2D6 phenotypes mischaracterised by non-LRS genetic tests (for samples with LRS and non-LRS data).RESULTSSix studies and 1411 samples were included. In a meta-analysis of four studies, IPS was 10% overall (95% CI = (2, 18); n = 1385), 20% amongst Oceanians (95% CI = (17, 23); n = 582) and 2% amongst Europeans (95% CI = (1, 4); n = 803). IPA was 4% in a large European cohort (95% CI = (2, 7); n = 567). When LRS was used selectively (e.g. for novel or complex CYP2D6 genotypes), very high figures were observed for IPS (e.g. 88%; 95% CI = (72, 100); n = 17; country = Japan) and IPA (e.g. 76%; 95% CI = (55, 98); n = 17; country = Japan).CONCLUSIONSLRS improves CYP2D6 phenotyping compared to established genetic tests, particularly amongst Oceanian and Japanese individuals, and those with novel or complex genotypes. LRS may therefore assist in optimising personalised prescribing of psychotropic medications. Further research is needed to determine associated clinical benefits, such as increased medication safety and efficacy.","PeriodicalId":16892,"journal":{"name":"Journal of Psychopharmacology","volume":"9 1","pages":"2698811241268899"},"PeriodicalIF":4.1,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142223997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Re-visiting the association between antidepressant use and the risk of lung cancer. 重新审视使用抗抑郁药与肺癌风险之间的关联。

IF 4.5 3区医学

Journal of Psychopharmacology Pub Date : 2024-09-01 Epub Date: 2024-08-08 DOI: 10.1177/02698811241268887

Ching-Fang Sun, Kuan-Pin Su, Anita S Kablinger

引用次数: 0

Common protein networks for various drug regimens of major depression are associated with complement and immunity. 重度抑郁症各种药物治疗方案的常见蛋白质网络与补体和免疫有关。

IF 4.5 3区医学

Journal of Psychopharmacology Pub Date : 2024-09-01 Epub Date: 2024-08-16 DOI: 10.1177/02698811241269683

Seungyeon Lee, Sora Mun, Jiyeong Lee, Hee-Gyoo Kang

{"title":"Common protein networks for various drug regimens of major depression are associated with complement and immunity.","authors":"Seungyeon Lee, Sora Mun, Jiyeong Lee, Hee-Gyoo Kang","doi":"10.1177/02698811241269683","DOIUrl":"10.1177/02698811241269683","url":null,"abstract":"Background: Major depressive disorder (MDD) can present a variety of clinical presentations and has high inter-individual heterogeneity. Multiple studies have suggested various subtype models related to symptoms, etiology, sex, and treatment response. Employing different regimens is common when treating MDD, and identifying effective therapeutics requires time. Frequent treatment attempts and failures can lead to a diagnosis of treatment resistance, and the heterogeneity of treatment responses among individuals makes it difficult to understand and interpret the biological mechanisms underlying MDD.Aim: This study explored the differentially expressed proteins and commonly altered protein networks across drug treatments by comparing the serum proteomes of patients with MDD treated with drug regimens (T-MDD, n = 20) and untreated patients (NT-MDD, n = 20).Methods: Differentially expressed proteins were profiled in non-drug-treated and drug-treated patients with depression using liquid chromatography-mass spectrometry. The common protein networks affected by different medications were studied.Results: Of the proteins profiled, 12 were significantly differentially expressed between the T-MDD and NT-MDD groups. Commonly altered proteins and networks of various drug treatments for depression were related to the complement system and immunity.Conclusions: Our results provide information on common biological changes across different pharmacological treatments employed for depression and provide an alternative perspective for improving our understanding of the biological mechanisms of drug response in MDD with great heterogeneity in the background of the disease.","PeriodicalId":16892,"journal":{"name":"Journal of Psychopharmacology","volume":" ","pages":"798-806"},"PeriodicalIF":4.5,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141988209","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evidence-based guidelines for the interpretation of the 9-item Concise Health Risk Tracking - Self-Report (CHRT-SR₉) measure of suicidal risk. 基于证据的 9 项简明健康风险追踪--自我报告（CHRT-SR9）自杀风险测量解释指南。

IF 4.5 3区医学

Journal of Psychopharmacology Pub Date : 2024-09-01 Epub Date: 2024-08-08 DOI: 10.1177/02698811241268875

Karabi Nandy, Rajesh Ranjan Nandy, A John Rush, Taryn L Mayes, Madhukar H Trivedi

{"title":"Evidence-based guidelines for the interpretation of the 9-item Concise Health Risk Tracking - Self-Report (CHRT-SR9) measure of suicidal risk.","authors":"Karabi Nandy, Rajesh Ranjan Nandy, A John Rush, Taryn L Mayes, Madhukar H Trivedi","doi":"10.1177/02698811241268875","DOIUrl":"10.1177/02698811241268875","url":null,"abstract":"Background: The 9-item Concise Health Risk Tracking - Self-Report (CHRT-SR9) is a widely used patient-reported outcome measure of suicidal risk. The goal of this article is to provide an evidence-based interpretation of the CHRT-SR9 total score in terms of four clinically actionable categories of suicidal risk (none, mild, moderate, and severe).Methods: Data from two large programs involving adolescents and adults were combined in this paper. In these studies, the CHRT-SR9 was anchored against an independent measure of suicidal risk, the suicide item (Item #9) in the Patient Health Questionnaire (PHQ-9), with categories 0 (none), 1 (mild), 2 (moderate), and 3 (severe). In the combined data (n = 1945), we calculated the cumulative percentage of data across these four categories and the percentile score of the CHRT-SR9 total score that corresponded to these percentages; from this, we developed ranges of the CHRT-SR9 total score that corresponded to the four categories of Item #9 of PHQ-9. We also calculated similar ranges for two broad subscales of the CHRT-SR9 total score; Propensity and Suicidal Thoughts. To assess the robustness of our findings, we repeated the analysis at another timepoint across studies.Results: Findings indicated that the CHRT-SR9 total score (range: 0-36) can be categorized as none (0-14), mild (15-21), moderate (22-26), and severe (27-36). Similar categories were calculated for the Propensity and Suicidal Thoughts subscales. The findings were the same when repeated at another timepoint.Conclusion: This categorization of the CHRT-SR9 total score can place patients into clinically meaningful and actionable categories of suicidal risk.","PeriodicalId":16892,"journal":{"name":"Journal of Psychopharmacology","volume":" ","pages":"784-788"},"PeriodicalIF":4.5,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11457466/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141906885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Insomnia and the effect of zolpidem-extended-release on the sleep items of the Hamilton Rating Scale for Depression in outpatients with depression, insomnia, and suicidal ideation: Relationship to patient age. 失眠以及唑吡坦缓释剂对抑郁症、失眠和自杀意念门诊患者汉密尔顿抑郁评分量表睡眠项目的影响：与患者年龄的关系。

IF 4.5 3区医学

Journal of Psychopharmacology Pub Date : 2024-09-01 Epub Date: 2024-08-09 DOI: 10.1177/02698811241268900

William V McCall, Kayla Mercado, Tess N Dzurny, Laryssa L McCloud, Andrew D Krystal, Ruth M Benca, Peter B Rosenquist, Stephen W Looney

{"title":"Insomnia and the effect of zolpidem-extended-release on the sleep items of the Hamilton Rating Scale for Depression in outpatients with depression, insomnia, and suicidal ideation: Relationship to patient age.","authors":"William V McCall, Kayla Mercado, Tess N Dzurny, Laryssa L McCloud, Andrew D Krystal, Ruth M Benca, Peter B Rosenquist, Stephen W Looney","doi":"10.1177/02698811241268900","DOIUrl":"10.1177/02698811241268900","url":null,"abstract":"Background: There are limited data regarding gamma-aminobutyric acid (GABA) allosteric modulator sleep-aid medications in persons with depression, insomnia, and suicidal ideation (SI).Aims: This secondary analysis examined the relationship of age to insomnia and the impact of age on the treatment of insomnia with zolpidem extended-release (zolpidem-ER) in depressed suicidal patients. A prior report found that the addition of zolpidem-ER promoted significantly superior reductions in global severity of insomnia in depressed outpatients with insomnia and SI over 8 weeks, but here we report the differences among early, middle, and late insomnia.Methods: This secondary analysis examined the three early, middle, and late insomnia items of the Hamilton Rating Scale for Depression (HRSD) and their relationship to age and responsiveness to treatment with zolpidem-ER. One hundred and three patients with major depression, SI, and insomnia received open-label serotonin reuptake inhibitors and were randomly allocated 1:1 to receive zolpidem-ER or placebo at bedtime. Results: Older age at baseline was associated with worse middle and late insomnia, but not with early insomnia. Subsequent treatment with zolpidem-ER produced superior improvement in early and middle insomnia, but not late insomnia.Conclusions: These findings are consistent with the known age-related advancement of sleep timing in the general population and depressed outpatients and with the expected effects of a short half-life GABA allosteric modulator sleep aid. By implication, prescribers of pharmacologic treatment of insomnia in depressed patients should consider an alternative to zolpidem-ER when late insomnia is a concern.Trial registration number: ClinicalTrials.gov Identifier: NCT01689909.","PeriodicalId":16892,"journal":{"name":"Journal of Psychopharmacology","volume":" ","pages":"827-831"},"PeriodicalIF":4.5,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141906887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0